{"content":"<li class=\"n-box-item date-title\" data-end=\"1507262399\" data-start=\"1507176000\" data-txt=\"Monday, December 23, 2019\">Thursday, October  5, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3299677\" data-ts=\"1507244453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSREY\" target=\"_blank\">SSREY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299677-swiss-re-to-allow-minority-reassure-stake-from-ms-and-ad\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Swiss Re to allow minority ReAssure stake from MS&amp;AD</a></h4><ul>   <li>Swiss Re (<a href=\"http://seekingalpha.com/symbol/SSREY\" target=\"_blank\">SSREY</a> <font color='green'>+0.4%</font>) has reached a deal that will allow Japan's MS&amp;AD Insurance Group (<a href=\"http://seekingalpha.com/symbol/MSADY\" target=\"_blank\">MSADY</a> <font color='red'>-1.6%</font>) to <a href=\"https://asia.nikkei.com/Business/Deals/Japan-s-MS-AD-Insurance-Group-to-take-stake-in-UK-insurer\" target=\"_blank\">make a minority investment</a> into its closed-book business, ReAssure.</li>    <li>MS&amp;AD will start with a 5% stake in ReAssure for &pound;175M (about $229.6M), an investment that values the closed-book unit at &pound;3.5B (about $4.59B).</li>    <li>The Japanese group has committed to invest &pound;800M in total (over a three-year period from closing) to attain a maximum stake of 15%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299677\" data-linked=\"Swiss Re to allow minority ReAssure stake from MS&amp;AD\" data-tweet=\"$SSREY $SSREY $MSADY - Swiss Re to allow minority ReAssure stake from MS&amp;AD https://seekingalpha.com/news/3299677-swiss-re-to-allow-minority-reassure-stake-from-ms-and-ad?source=tweet\" data-url=\"https://seekingalpha.com/news/3299677-swiss-re-to-allow-minority-reassure-stake-from-ms-and-ad\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299675\" data-ts=\"1507243861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299675-house-panel-invites-facebook-twitter-google-to-nov-1-hearing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">House panel invites Facebook, Twitter, Google to Nov. 1 hearing</a></h4><ul>   <li>Executives from Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+1.7%</font>), Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='green'>+2.8%</font>) and Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='green'>+1.9%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='green'>+1.9%</font>) have been invited to a <a href=\"https://www.reuters.com/article/us-usa-trump-russia-socialmedia/social-media-executives-to-testify-nov-1-about-russia-and-u-s-election-idUSKBN1CA2VC\" target=\"_blank\">public hearing of the House Intelligence Committee</a> Nov. 1, to testify about Russian meddling in the 2016 U.S. election.</li>    <li>That's a matching set with those executives' scheduled appearance the same day before the Senate Intelligence Committee, already investigating the same issues.</li>    <li>Facebook so far has confirmed that its officials would testify, while Google and Twitter have yet to comment.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299675\" data-linked=\"House panel invites Facebook, Twitter, Google to Nov. 1 hearing\" data-tweet=\"$GOOG $GOOG $GOOGL - House panel invites Facebook, Twitter, Google to Nov. 1 hearing https://seekingalpha.com/news/3299675-house-panel-invites-facebook-twitter-google-to-nov-1-hearing?source=tweet\" data-url=\"https://seekingalpha.com/news/3299675-house-panel-invites-facebook-twitter-google-to-nov-1-hearing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299674\" data-ts=\"1507243137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIGA\" target=\"_blank\">GIGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299674-giga-tronicsplus-64-on-4_9m-aircraft-filter-order\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Giga-tronics +64% on $4.9M aircraft filter order</a></h4><ul>     <li>Giga-tronics (<a href='https://seekingalpha.com/symbol/GIGA' title='Giga-tronics Incorporated'>OTC:GIGA</a>) <font color='green'>+64.3%</font> after-hours on news of an additional $4.9M order extending ongoing production of its high performance RADAR filters used in fighter jet aircraft for a \"major aerospace company.\"</li>     <li>GIGA expects to begin initial shipments of the new order during FQ4 and complete the bulk of the new order shipments over the succeeding 9 -12 months.</li>     <li>GIGA also offers guidance on its 2018 Q2, which ended on Sept. 30, seeing net sales of $2M-$2.2M, vs. $2M in FQ1 and $4.4M in the year-ago quarter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299674\" data-linked=\"Giga-tronics +64% on $4.9M aircraft filter order\" data-tweet=\"$GIGA - Giga-tronics +64% on $4.9M aircraft filter order https://seekingalpha.com/news/3299674-giga-tronicsplus-64-on-4_9m-aircraft-filter-order?source=tweet\" data-url=\"https://seekingalpha.com/news/3299674-giga-tronicsplus-64-on-4_9m-aircraft-filter-order\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299669\" data-ts=\"1507239426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COST\" target=\"_blank\">COST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299669-costcominus-2_9-despite-solid-comp-sales-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Costco -2.9% despite solid comp sales, Q4 beat</a></h4><ul>   <li>Costco Wholesale (NASDAQ:<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a>) is <font color='red'>2.9% lower</font> postmarket despite posting <a href=\"https://seekingalpha.com/news/3299641-costco-wholesale-beats-0_06-beats-revenue\" target=\"_blank\">Q4 earnings</a> that beat expectations, thanks in part to higher membership fees but also including more U.S. sales.</li>    <li>Comp sales (excluding impacts from gas price changes and forex) for the 17 weeks were up 5.7%; up 5.8% in U.S., up 4.8% in Canada, and 6% elsewhere internationally.</li><li>Meanwhile, membership fees (which made up about 72% of operating income last year) were up 13% to $943M.</li>    <li>Net income was $919M, up 18% from $779M last year (this year's Q4 was 17 weeks, vs. 16 weeks a year ago).</li>    <li>The company wrapped the fiscal year with 741 warehouses: 514 in U.S./Puerto Rico, 97 in Canada, 37 in Mexico, 28 in UK, 26 in Japan, 13 in Korea, 13 in Taiwan, nine in Australia, two in Spain, one in France and one in Iceland.</li><li>It had 49.4M&nbsp;members at fiscal year-end.</li>    <li><a href=\"https://seekingalpha.com/pr/16961441-costco-wholesale-corporation-reports-fourth-quarter-fiscal-year-2017-operating-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3299669\" data-linked=\"Costco -2.9% despite solid comp sales, Q4 beat\" data-tweet=\"$COST - Costco -2.9% despite solid comp sales, Q4 beat https://seekingalpha.com/news/3299669-costcominus-2_9-despite-solid-comp-sales-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3299669-costcominus-2_9-despite-solid-comp-sales-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>91&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299668\" data-ts=\"1507239347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299668-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+19.4%</font>. <a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color='green'>+4.8%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/YUMC' title='Yum China'>YUMC</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/ATTO' title='Atento'>ATTO</a> <font color='green'>+1.8%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color='red'>-2.8%</font>. ITEK <font color='red'>-2.0%</font>. <a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a> <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a> <font color='red'>-1.7%</font>. <a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='red'>-1.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299668\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$SNCR $ADMS $APVO - After Hours Gainers / Losers https://seekingalpha.com/news/3299668-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299668-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299666\" data-ts=\"1507238713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YUMC\" target=\"_blank\">YUMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299666-yum-chinaplus-3_5-on-establishing-dividend-planning-for-wat-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yum China +3.5% on establishing dividend, planning for Wat as new CEO</a></h4><ul>     <li>Yum China (NYSE:<a href='https://seekingalpha.com/symbol/YUMC' title='Yum China'>YUMC</a>) <font color='green'>+3.5%</font>&nbsp;after-hours despite missing <a href=\"https://seekingalpha.com/news/3299651-yum-china-misses-0_04-beats-revenue\" target=\"_blank\">Q3 earnings</a> expectations, as the company announces its <a href=\"https://seekingalpha.com/news/3299652-yum-china-declares-0_10-dividend\" target=\"_blank\">first-ever dividend</a>, an increased stock buyback plan and a CEO succession plan.</li>     <li>YUMC's first quarterly dividend will total $0.10/share, and the stock repurchase authorization has been increased to $550M from $300M.</li>     <li>Joey Wat, the company's President and COO since February, will succeed Mickey Pant as CEO in March 2018; she joined YUMC in 2014, first serving as President of KFC China and then as CEO of KFC China.</li>     <li>Pant has served as CEO and a board member of YUMC since its spinoff from Yum! Brands and previously as CEO of Yum! Restaurants China.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299666\" data-linked=\"Yum China +3.5% on establishing dividend, planning for Wat as new CEO\" data-tweet=\"$YUMC - Yum China +3.5% on establishing dividend, planning for Wat as new CEO https://seekingalpha.com/news/3299666-yum-chinaplus-3_5-on-establishing-dividend-planning-for-wat-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3299666-yum-chinaplus-3_5-on-establishing-dividend-planning-for-wat-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299664\" data-ts=\"1507237433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299664-disney-altice-usa-set-multi-year-carriage-renewal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney, Altice USA set multi-year carriage renewal</a></h4><ul>   <li>After extending their carriage deal past a scheduled weekend expiration, Walt Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-0.4%</font>) and Altice USA (<a href=\"http://seekingalpha.com/symbol/ATUS\" target=\"_blank\">ATUS</a> <font color='green'>+4.5%</font>) have come to a comprehensive new agreement.</li>    <li>The multi-year renewal covers access for Optimum TV customers to a variety of Disney's channels, including WABC, Disney Channel, Disney Junior, Disney XD, ESPN, ESPN2, ESPNU, ESPNEWS, ESPN Deportes, ESPN Goal Line, ESPN Bases Loaded, ESPN3 and Freeform.</li>    <li>As speculated, Optimum will add ESPN's SEC Network (in late 2018) and launch ACC Network in place of another ESPN network in August 2019.</li>    <li>The two will also work together on the planned ESPN direct-to-consumer offering, set for early 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298776-disney-plus-1_5-percent-altice-usa-plus-1_1-percent-deal-averts-channel-blackout\" target=\"_blank\">Disney +1.5%, Altice USA +1.1% after deal averts channel blackout</a> (Oct. 02 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298573-altice-usa-disney-reach-deal-program-interruption\" target=\"_blank\">Altice USA, Disney reach deal with no program interruption</a> (Oct. 02 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299664\" data-linked=\"Disney, Altice USA set multi-year carriage renewal\" data-tweet=\"$DIS $DIS $ATUS - Disney, Altice USA set multi-year carriage renewal https://seekingalpha.com/news/3299664-disney-altice-usa-set-multi-year-carriage-renewal?source=tweet\" data-url=\"https://seekingalpha.com/news/3299664-disney-altice-usa-set-multi-year-carriage-renewal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299655\" data-ts=\"1507236873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299655-synchronoss-soars-on-resuming-strategic-alternative-talks-siris\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss soars on resuming strategic alternative talks with Siris</a></h4><ul><li>        Synchronoss (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <a href=\"https://seekingalpha.com/pr/16961496-synchronoss-technologies-provides-update-strategic-alternatives-process\" target=\"_blank\">announces</a> resuming strategic alternative talks with Siris Capital Partners.</li><li>               Synchronoss had previously ended talks to pursue other offers after Siris demanded an exclusivity agreement.&nbsp;</li><li>           The new talks, which come with &ldquo;improved terms&rdquo;, will have a limited exclusivity period to allow for negotiations between the companies. &nbsp; </li><li>                  Synchronoss shares are&nbsp;<font color='green'>up 17.63%</font>&nbsp;aftermarket.&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3298713-synchronoss-shares-soar-strategic-transaction-talks\" target=\"_blank\">Synchronoss shares soar on strategic transaction talks</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299655\" data-linked=\"Synchronoss soars on resuming strategic alternative talks with Siris\" data-tweet=\"$SNCR - Synchronoss soars on resuming strategic alternative talks with Siris https://seekingalpha.com/news/3299655-synchronoss-soars-on-resuming-strategic-alternative-talks-siris?source=tweet\" data-url=\"https://seekingalpha.com/news/3299655-synchronoss-soars-on-resuming-strategic-alternative-talks-siris\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299653\" data-ts=\"1507236183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZGNX\" target=\"_blank\">ZGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299653-zogenix-closes-equity-offering-raises-almost-289m-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zogenix closes equity offering, raises almost $289M; shares down 2% after hours</a></h4><ul><li>Zogenix (NASDAQ:<a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a>) <a href=\"https://seekingalpha.com/pr/16961494-zogenix-announces-closing-public-offering-common-stock-including-full-exercise-underwriters\" target=\"_blank\">closes </a>its public offering of ~7.7M shares of common stock at $37.50 per share yielding gross proceeds of ~$288.9M. Net proceeds will fund the continued development of ZX008, working capital and general corporate purposes.</li><li>Shares are off&nbsp;<font color='red'>2%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299653\" data-linked=\"Zogenix closes equity offering, raises almost $289M; shares down 2% after hours\" data-tweet=\"$ZGNX - Zogenix closes equity offering, raises almost $289M; shares down 2% after hours https://seekingalpha.com/news/3299653-zogenix-closes-equity-offering-raises-almost-289m-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3299653-zogenix-closes-equity-offering-raises-almost-289m-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299651\" data-ts=\"1507235551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YUMC\" target=\"_blank\">YUMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299651-yum-china-misses-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yum China misses by $0.04, beats on revenue</a></h4><ul><li>Yum China (NYSE:<a href='https://seekingalpha.com/symbol/YUMC' title='Yum China'>YUMC</a>): Q3 EPS of $0.52 <font color='red'>misses by $0.04</font>.</li><li>Revenue of $2.04B (+8.5% Y/Y) <font color='green'>beats by $60M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16961482-yum-china-reports-6-percent-store-sales-growth-10-percent-system-sales-growth-operating'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299651\" data-linked=\"Yum China misses by $0.04, beats on revenue\" data-tweet=\"$YUMC - Yum China misses by $0.04, beats on revenue https://seekingalpha.com/news/3299651-yum-china-misses-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3299651-yum-china-misses-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299648\" data-ts=\"1507235418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299648-lilly-prevails-in-challenge-to-patent-covering-vitamin-regimen-for-lung-cancer-med-alimta\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly prevails in challenge to patent covering vitamin regimen for lung cancer med Alimta; shares up 1% after hours</a></h4><ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;after hours in response to the news of a <a href=\"https://seekingalpha.com/pr/16961425-u-s-patent-trademark-office-rules-lillys-favor-alimta-vitamin-regimen-patent\" target=\"_blank\">favorable ruling</a> in a challenge to its patented vitamin regimen for lung cancer drug <a href=\"https://www.alimta.com/\" target=\"_blank\">Alimta</a> (pemetrexed for injection).</li><li>In an inter partes review initiated by Neptune Generics and Novartis' (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) Sandoz, the USPTO's Patent Trial and Appeal Board &#40;PTAB&#41; found that all claims of the patent covering the vitamin regimen are valid. If upheld through all remaining challenges, Alimta will maintain U.S. exclusivity until May 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299648\" data-linked=\"Lilly prevails in challenge to patent covering vitamin regimen for lung cancer med Alimta; shares up 1% after hours\" data-tweet=\"$LLY $LLY $NVS - Lilly prevails in challenge to patent covering vitamin regimen for lung cancer med Alimta; shares up 1% after hours https://seekingalpha.com/news/3299648-lilly-prevails-in-challenge-to-patent-covering-vitamin-regimen-for-lung-cancer-med-alimta?source=tweet\" data-url=\"https://seekingalpha.com/news/3299648-lilly-prevails-in-challenge-to-patent-covering-vitamin-regimen-for-lung-cancer-med-alimta\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299646\" data-ts=\"1507235190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299646-annaly-capitalminus-2_3-on-word-of-65m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Annaly Capital -2.3% on word of 65M-share offering</a></h4><ul>     <li>Annaly Capital Management (NYSE:<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a>) is <font color='red'>2.3% lower</font> in postmarket trading after announcing it will <a href=\"https://seekingalpha.com/pr/16961422-annaly-capital-management-inc-announces-public-offering-common-stock\" target=\"_blank\">offer 65M shares of common stock</a>.</li>     <li>Underwriters will have a 30-day greenshoe option to buy up to 9.75M shares more.</li>     <li>Net proceeds will go to \"acquired targeted assets\" under the company's capital allocation policy</li>     <li>Joint book-runners are Credit Suisse, BofA Merrill Lynch, Goldman Sachs &amp; Co. LLC and Wells Fargo Securities.</li>   <li><b>Updated:</b> Bloomberg says the shares are likely to be offered at $12 each; <a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> is <font color='red'>down 2.3%</font> to $12.10 after hours after closing up, at $12.38.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299646\" data-linked=\"Annaly Capital -2.3% on word of 65M-share offering\" data-tweet=\"$NLY - Annaly Capital -2.3% on word of 65M-share offering https://seekingalpha.com/news/3299646-annaly-capitalminus-2_3-on-word-of-65m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3299646-annaly-capitalminus-2_3-on-word-of-65m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299645\" data-ts=\"1507234920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBPB\" target=\"_blank\">PBPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299645-potbelly-settles-ancora-adds-boehm-to-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potbelly settles with Ancora, adds Boehm to board</a></h4><ul>   <li>Potbelly (<a href=\"http://seekingalpha.com/symbol/PBPB\" target=\"_blank\">PBPB</a> <font color='green'>+1.7%</font>) has reached a settlement with activist investor Ancora Advisors in which it's <a href=\"https://seekingalpha.com/pr/16961408-potbelly-names-new-director\" target=\"_blank\">adding Ancora Portfolio Manager Joseph Boehm</a> to its board.</li>    <li>Boehm's initial term will run through the company's 2018 annual meeting, and he'll be on the slate for re-election then.</li>    <li>Boehm or an Ancora replacement will also serve on the Nominating and Corporate Governance Committee and on the Strategic Review Committee.</li>    <li>The settlement agreement will continue until 30 days prior to the last day of the advance notice deadline for the 2019 annual meeting or 30 days after the last day that an Ancora rep serves on the board, whichever is later.</li>    <li>Ancora had <a href=\"https://seekingalpha.com/news/3275072-activist-takes-aim-potbelly-reuters\" target=\"_blank\">written to the board</a> this summer urging strategy changes or (failing that) a sale of the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299645\" data-linked=\"Potbelly settles with Ancora, adds Boehm to board\" data-tweet=\"$PBPB - Potbelly settles with Ancora, adds Boehm to board https://seekingalpha.com/news/3299645-potbelly-settles-ancora-adds-boehm-to-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3299645-potbelly-settles-ancora-adds-boehm-to-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299633\" data-ts=\"1507233567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRZO\" target=\"_blank\">CRZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299633-carrizo-oil-sees-q3-output-above-midpoint-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carrizo Oil sees Q3 output above midpoint of guidance</a></h4><ul>     <li>Carrizo Oil &amp;&nbsp;Gas (<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='green'>+3.9%</font>) surged as much as 6% after <a href=\"https://seekingalpha.com/pr/16960332-carrizo-oil-and-gas-provides-update-operations-hedging-announces-third-quarter-2017-financial\" target=\"_blank\">raising its Q3 production outlook</a> above the midpoint of its previous  forecast range, or ~54.1K boe/day.</li>     <li>But CRZO also trims its Q3 sales forecast to a new range of 34.7K-34.9K bbl/day, vs. prior guidance of 35.4K-35.8K bbl/day, explaining that while its operations were not directly affected by Hurricane Harvey,  sales volumes temporarily declined because of flooding at third-party refineries, pipelines and other infrastructure facilities following the storm.</li>     <li>CRZO also says it has continued to add to its crude oil hedge       position through year-end 2018, and now has Q4 2017 swaps covering 15K bbl/day of crude oil at an average fixed price of $53.44/bbl.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299633\" data-linked=\"Carrizo Oil sees Q3 output above midpoint of guidance\" data-tweet=\"$CRZO - Carrizo Oil sees Q3 output above midpoint of guidance https://seekingalpha.com/news/3299633-carrizo-oil-sees-q3-output-above-midpoint-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3299633-carrizo-oil-sees-q3-output-above-midpoint-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299631\" data-ts=\"1507232565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USEG\" target=\"_blank\">USEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299631-us-energyplus-22-on-exchange-agreement-to-cut-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">US Energy +22% on exchange agreement to cut debt</a></h4><ul>     <li>US Energy (<a href='https://seekingalpha.com/symbol/USEG' title='U.S. Energy Corp.'>USEG</a> <font color='green'>+21.9%</font>) soars as much as 82% after announcing an agreement to substantially reduce its outstanding debt through an <a href=\"https://globenewswire.com/news-release/2017/10/05/1141284/0/en/U-S-Energy-Corp-Announces-Strategic-Partnership-and-Deleveraging-Transaction.html\" target=\"_blank\">exchange transaction</a> with APEG Energy II, the sole lender for the company's senior secured credit facility.</li>     <li>The lender will swap $4.5M in outstanding debt for ~5.82M new common shares, with USEG issuing more than 7.63M shares priced at $0.77 each, a 1.3% premium to the volume-weighted average price for the stock over the past 30 days.</li>     <li>USEG says the deal will reduce its annual interest payments by 84% while providing flexibility to increase its capital budget out of operating cash flow and participate in production growth.</li>     <li>Following the close of the transaction, APEG will hold 49.9% of USEG's outstanding common shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299631\" data-linked=\"US Energy +22% on exchange agreement to cut debt\" data-tweet=\"$USEG - US Energy +22% on exchange agreement to cut debt https://seekingalpha.com/news/3299631-us-energyplus-22-on-exchange-agreement-to-cut-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3299631-us-energyplus-22-on-exchange-agreement-to-cut-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299625\" data-ts=\"1507230652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGR\" target=\"_blank\">RGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299625-nra-appears-open-to-regulation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NRA appears open to more regulation</a></h4><ul><li>\"The NRA believes that devices designed to allow semi-automatic rifles to function like fully-automatic rifles should be subject to additional regulations,\" <a href=\"https://home.nra.org/joint-statement/\" target=\"_blank\">says the group</a>, referring to the bump fire stocks used in this week's Las Vegas shooting.</li><li>Among the interested players: Sturm Ruger (<a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company Inc.'>RGR</a> <font color='green'>+1.5%</font>), Vista Outdoor (<a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a> <font color='green'>+0.9%</font>), ShotSpotter (<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a> <font color='green'>+9.3%</font>), American Outdoor Brands (<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-0.6%</font>),</li></ul><div class=\"tiny-share-widget\" data-id=\"3299625\" data-linked=\"NRA appears open to more regulation\" data-tweet=\"$RGR $RGR $VSTO - NRA appears open to more regulation https://seekingalpha.com/news/3299625-nra-appears-open-to-regulation?source=tweet\" data-url=\"https://seekingalpha.com/news/3299625-nra-appears-open-to-regulation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>276&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299624\" data-ts=\"1507230109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PENN\" target=\"_blank\">PENN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299624-penn-national-and-pinnacle-entertainment-in-merger-talks-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Penn National and Pinnacle Entertainment in merger talks - WSJ</a></h4><ul><li>The talks have been on-again, off-again, and there's yet to be an agreement, but Penn National (<a href='https://seekingalpha.com/symbol/PENN' title='Penn National Gaming, Inc.'>PENN</a> <font color='green'>+4.2%</font>) remains interested in buying Pinnacle (<a href='https://seekingalpha.com/symbol/PNK' title='Pinnacle Entertainment, Inc.'>PNK</a> <font color='green'>+8.7%</font>), <a href=\"https://www.wsj.com/articles/penn-national-pinnacle-entertainment-consider-merger-1507229627\" target=\"_blank\">according to the report</a>.</li><li>The combined enterprise value of the two would be about $12B (well more than half of that being debt).</li></ul><div class=\"tiny-share-widget\" data-id=\"3299624\" data-linked=\"Penn National and Pinnacle Entertainment in merger talks - WSJ\" data-tweet=\"$PENN $PENN $PNK - Penn National and Pinnacle Entertainment in merger talks - WSJ https://seekingalpha.com/news/3299624-penn-national-and-pinnacle-entertainment-in-merger-talks-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3299624-penn-national-and-pinnacle-entertainment-in-merger-talks-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299621\" data-ts=\"1507229738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299621-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck Mobilisa, Inc.'>IDN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299621\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$NETE $HMNY $SMSI - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3299621-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299621-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299616\" data-ts=\"1507228352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HFC\" target=\"_blank\">HFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299616-refiners-slip-senators-warn-epa-on-fuel-mandates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Refiners slip as senators warn EPA on fuel mandates</a></h4><ul>     <li>Shares of oil refiners slide to session lows after a group of 38 U.S. senators <a href=\"http://www.reuters.com/article/us-usa-environment-biofuels/senators-object-to-plan-to-lower-u-s-renewable-fuel-requirements-for-2018-letter-idUSKBN1CA2AF?il=0\" target=\"_blank\">asks the EPA not to make changes</a> to U.S. renewable fuel mandates, including  possible reductions in annual quotas for biodiesel and cellulosic ethanol.</li><li>The senators, including Sen. Grassley of Iowa, say in the letter that the EPA should restructure its proposal for the 2018  version of a rule that each year forces producers of oil-based fuels to  include renewable fuels such as ethanol in their products.</li><li>&ldquo;The rule unjustifiably flatlines biomass-based diesel, reduces advanced  biofuels and reduces the cellulosic biofuel blending target by about 25%,&rdquo; the letter says. &ldquo;The final rule should address these  shortfalls.&rdquo;</li>     <li><a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='red'>-3.1%</font>, <a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='red'>-1.7%</font>, <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='red'>-0.8%</font>, <a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-0.6%</font>, <a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='red'>-0.2%</font>, <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='red'>-0.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299616\" data-linked=\"Refiners slip as senators warn EPA on fuel mandates\" data-tweet=\"$HFC $HFC $CVRR - Refiners slip as senators warn EPA on fuel mandates https://seekingalpha.com/news/3299616-refiners-slip-senators-warn-epa-on-fuel-mandates?source=tweet\" data-url=\"https://seekingalpha.com/news/3299616-refiners-slip-senators-warn-epa-on-fuel-mandates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299613\" data-ts=\"1507227839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299613-eli-lillys-209-alimta-patent-claims-upheld-shares-up-1_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eli Lilly&#39;s &#39;209 Alimta patent claims upheld; shares up 1.1%</a></h4><ul><li><a href=\"https://www.scribd.com/document/360797896/Eli-Lilly-209-Alimta-IPR-Final-Written-Decision\" target=\"_blank\">Full decision here</a></li><li><a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>&nbsp;<font color='green'>+1.1%</font>&nbsp;vs. about flat ahead of the news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299613\" data-linked=\"Eli Lilly&#39;s &#39;209 Alimta patent claims upheld; shares up 1.1%\" data-tweet=\"$LLY - Eli Lilly&#39;s &#39;209 Alimta patent claims upheld; shares up 1.1% https://seekingalpha.com/news/3299613-eli-lillys-209-alimta-patent-claims-upheld-shares-up-1_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299613-eli-lillys-209-alimta-patent-claims-upheld-shares-up-1_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299611\" data-ts=\"1507227158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYD\" target=\"_blank\">BYD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299611-jpmorgan-sees-upside-for-boyd-gaming\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan sees upside for Boyd Gaming</a></h4><ul> <li>JPMorgan is positive on Boyd Gaming (NYSE:<a href='https://seekingalpha.com/symbol/BYD' title='Boyd Gaming Corporation'>BYD</a>) after meeting with management.</li> <li>Analyst Joseph Gref sees multiple levers that Boyd can pull to improve margins and likes the exposure of the casino operator to the Las Vegas locals market.</li> <li>JP has a year-end price target on Boyd of $32.</li> <li>Shares are <font color='green'>up 4.18%</font> today on heavy volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299611\" data-linked=\"JPMorgan sees upside for Boyd Gaming\" data-tweet=\"$BYD - JPMorgan sees upside for Boyd Gaming https://seekingalpha.com/news/3299611-jpmorgan-sees-upside-for-boyd-gaming?source=tweet\" data-url=\"https://seekingalpha.com/news/3299611-jpmorgan-sees-upside-for-boyd-gaming\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299609\" data-ts=\"1507226434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299609-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SYNL' title='Synalloy Corporation'>SYNL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+9%</font>. PGH <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ALO' title='Alio Gold Inc'>ALO</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299609\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$DELT-OLD $SYNL $YTEN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3299609-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299609-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299606\" data-ts=\"1507225736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299606-sanofi-ready-to-launch-sale-of-european-generic-business-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi ready to launch sale of European generic business; shares up 1%</a></h4><ul><li>Le Figaro <a href=\"http://www.lefigaro.fr/societes/2017/10/05/20005-20171005ARTFIG00310-sanofi-lance-la-vente-de-ses-generiques-en-europe.php\" target=\"_blank\">reports </a>that Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.7%</font>) is poised to start the process of selling its generics business in Europe, marketed under the Zentiva brand. The unit generated sales of &euro;800M in 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299606\" data-linked=\"Sanofi ready to launch sale of European generic business; shares up 1%\" data-tweet=\"$SNY - Sanofi ready to launch sale of European generic business; shares up 1% https://seekingalpha.com/news/3299606-sanofi-ready-to-launch-sale-of-european-generic-business-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299606-sanofi-ready-to-launch-sale-of-european-generic-business-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299605\" data-ts=\"1507225307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299605-tevas-copaxone-facing-generic-competition-in-europe-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva&#39;s Copaxone facing generic competition in Europe; shares down 1%</a></h4><ul><li>The FDA's approval of Mylan's generic version of Teva Pharmaceutical Industries' (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-1.1%</font>) top selling Copaxone (glatiramer acetate) at both the 40 mg and 20 mg strengths is not its only headache.</li><li>Apparently, privately held firms Alvogen, based in South Korea, and Dutch outfit Synthon just received <a href=\"http://in.reuters.com/article/mylan-nl-stocks-teva-pharm-ind/mylan-surges-teva-slumps-after-fda-approves-copaxone-copy-idINKBN1CA07Z?feedType=RSS&amp;feedName=health&amp;utm_source=Twitter&amp;utm_medium=Social&amp;utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29\" target=\"_blank\">approval</a> in Europe to market a generic 40 mg version, the more popular dose. The companies already promote the 20 mg version.</li><li>Mylan <a href=\"https://seekingalpha.com/pr/16961220-mylan-partnership-synthon-receives-marketing-authorization-approval-europe-first-generic\" target=\"_blank\">plans to promote </a>the 40 mg version in Europe per its partnership with Synthon. It says it has exclusive distribution rights in Western Europe and Scandinavia.</li><li>Copaxone sales in Europe are ~$590M, about 15% of the drug's $4B global sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299605\" data-linked=\"Teva&#39;s Copaxone facing generic competition in Europe; shares down 1%\" data-tweet=\"$TEVA - Teva&#39;s Copaxone facing generic competition in Europe; shares down 1% https://seekingalpha.com/news/3299605-tevas-copaxone-facing-generic-competition-in-europe-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299605-tevas-copaxone-facing-generic-competition-in-europe-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299602\" data-ts=\"1507224032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLNO\" target=\"_blank\">SLNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299602-soleno-therapeutics-to-reverse-split-stock-1-5-effective-tomorrow-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soleno Therapeutics to reverse split stock 1:5 effective tomorrow; shares down 7%</a></h4><ul><li>With the aim of regaining compliance with Nasdaq's listing requirement of a $1 minimum bid price, Soleno Therapeutics (<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a> <font color='red'>-6.5%</font>) will <a href=\"https://seekingalpha.com/pr/16961199-soleno-therapeutics-announces-1minus-5-reverse-stock-split\" target=\"_blank\">execute </a>a 1:5 reverse split of its common stock after the close. Post-split trading will commence tomorrow, October 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299602\" data-linked=\"Soleno Therapeutics to reverse split stock 1:5 effective tomorrow; shares down 7%\" data-tweet=\"$SLNO - Soleno Therapeutics to reverse split stock 1:5 effective tomorrow; shares down 7% https://seekingalpha.com/news/3299602-soleno-therapeutics-to-reverse-split-stock-1-5-effective-tomorrow-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3299602-soleno-therapeutics-to-reverse-split-stock-1-5-effective-tomorrow-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299600\" data-ts=\"1507223583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299600-new-trial-ordered-in-sanofi-regeneron-fight-amgen-over-pcsk9-inhibitor-patents\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New trial ordered in Sanofi/Regeneron fight with Amgen over PCSK9 inhibitor patents</a></h4><ul><li>An appeals court has <a href=\"https://seekingalpha.com/pr/16961172-appellate-court-orders-new-trial-vacates-permanent-injunction-ongoing-patent-case-regarding\" target=\"_blank\">ordered a new trial</a> in Amgen's (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-1.5%</font>) dispute with Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.5%</font>) and Regeneron (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+4.4%</font>) over patents related to cholesterol drugs Repatha (evolocumab) and Praluent (alirocumab). The ruling also vacates the district court's injunction barring the promotion and manufacture of Praluent by Sanofi and Regeneron.</li><li>The appeals court found that the district court erred by excluding evidence regarding written description and enablement, improperly instructing the jury on written description and improperly granting a permanent injunction.</li><li>It did, however, affirm the district court's ruling that Amgen's patents were non-obvious, a general requirement for patentability, one of Sanofi and Regeneron's challenges. Citing the exclusion of evidence, the court considered the record to be incomplete and concluded that Sanofi and Regeneron were not entitled to judgement on the issues of written description and enablement.</li><li>The schedule for the new trial has not yet been determined.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299556-sanofi-and-regeneron-win-appeal-pcsk9-patent-ruling-versus-amgen\" target=\"_blank\">Sanofi &amp; Regeneron win appeal of PCSK9 patent ruling versus Amgen</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299600\" data-linked=\"New trial ordered in Sanofi/Regeneron fight with Amgen over PCSK9 inhibitor patents\" data-tweet=\"$AMGN $AMGN $SNY - New trial ordered in Sanofi/Regeneron fight with Amgen over PCSK9 inhibitor patents https://seekingalpha.com/news/3299600-new-trial-ordered-in-sanofi-regeneron-fight-amgen-over-pcsk9-inhibitor-patents?source=tweet\" data-url=\"https://seekingalpha.com/news/3299600-new-trial-ordered-in-sanofi-regeneron-fight-amgen-over-pcsk9-inhibitor-patents\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299595\" data-ts=\"1507222792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299595-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ENVA' title='Enova International, Inc.'>ENVA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299595\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$NAVI $JTPY $ENVA - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3299595-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299595-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299587\" data-ts=\"1507221918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299587-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ONVI' title='Onvia, Inc.'>ONVI</a> <font color='green'>+96%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+32%</font>. ITEK <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='green'>+21%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/DRAD' title='Digirad Corporation'>DRAD</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck Mobilisa, Inc.'>IDN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/MNOV' title='MediciNova, Inc.'>MNOV</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a> <font color='red'>-13%</font>. EBIO <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CKPT' title='CHECKPOINT THERAPEUTICS'>CKPT</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299587\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ONVI $MNKD $APVO - Midday Gainers / Losers https://seekingalpha.com/news/3299587-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299587-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299585\" data-ts=\"1507221031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299585-fda-designates-athersys-multistem-cell-therapy-for-accelerated-approval-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA designates Athersys&#39; MultiStem cell therapy for accelerated approval; shares ahead 8%</a></h4><ul><li>Athersys (<a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='green'>+7.5%</font>) heads north on modestly higher volume on the <a href=\"https://seekingalpha.com/pr/16960389-athersys-present-2017-cell-and-gene-meeting-mesa-announces-regenerative-medicine-advanced\" target=\"_blank\">news </a>that the FDA has designated MultiStem a Regenerative Medicine Advanced Therapy &#40;RMAT&#41;, a status for eligible cell and regenerative medicine treatments that provides for more intensive development guidance from the agency and priority review/accelerated approval of the marketing application.</li><li><a href=\"http://www.athersys.com/msOverview.cfm\" target=\"_blank\">MultiStem cell therapy</a> is a patented regenerative medicine product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage.</li><li>Later today, the company will present an overview of its neuroscience programs at the Cell &amp; Gene Meeting on the Mesa in La Jolla, CA.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286162-key-regulators-board-athersys-clinical-development-plan-multistem-shares-ahead-2-percent\" target=\"_blank\">Key regulators on board with Athersys' clinical development plan for MultiStem; shares ahead 2% premarket</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299585\" data-linked=\"FDA designates Athersys&#39; MultiStem cell therapy for accelerated approval; shares ahead 8%\" data-tweet=\"$ATHX - FDA designates Athersys&#39; MultiStem cell therapy for accelerated approval; shares ahead 8% https://seekingalpha.com/news/3299585-fda-designates-athersys-multistem-cell-therapy-for-accelerated-approval-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3299585-fda-designates-athersys-multistem-cell-therapy-for-accelerated-approval-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299582\" data-ts=\"1507219843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299582-amgen-to-stay-course-in-pcsk9-inhibitor-patent-fight-sanofi-regeneron\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen to stay the course in PCSK9 inhibitor patent fight with Sanofi/Regeneron</a></h4><ul><li>In a statement to Seeking Alpha after the appeals court ruling in the Repatha/Praluent patent litigation, Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-2%</font>) says, \"Our ability to discover and deliver new medicines that benefit patients depends on meaningful patent protection and enforcement that enable significant investments in drug development and clinical trials. We are disappointed by the Court&rsquo;s action in reversing and remanding the district court&rsquo;s decision with respect to validity of our patents based on select pre-trial rulings.&nbsp;The Court, however, also rejected a main argument brought by defendants in seeking to overturn the injunction. We firmly believe in the validity of our patents and we look forward to reasserting our rights in court.\"</li><li>(<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.3%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299556-sanofi-and-regeneron-win-appeal-pcsk9-patent-ruling-versus-amgen\" target=\"_blank\">Sanofi &amp; Regeneron win appeal of PCSK9 patent ruling versus Amgen</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299582\" data-linked=\"Amgen to stay the course in PCSK9 inhibitor patent fight with Sanofi/Regeneron\" data-tweet=\"$AMGN $AMGN $REGN - Amgen to stay the course in PCSK9 inhibitor patent fight with Sanofi/Regeneron https://seekingalpha.com/news/3299582-amgen-to-stay-course-in-pcsk9-inhibitor-patent-fight-sanofi-regeneron?source=tweet\" data-url=\"https://seekingalpha.com/news/3299582-amgen-to-stay-course-in-pcsk9-inhibitor-patent-fight-sanofi-regeneron\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299579\" data-ts=\"1507219346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299579-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299579\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ABAC-OLD $SORL $KNDI - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3299579-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299579-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299578\" data-ts=\"1507219263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299578-athenexs-late-stage-study-comparing-oraxol-to-taxol-to-continue-planned-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenex&#39;s late-stage study comparing Oraxol to Taxol to continue as planned; shares up 1%</a></h4><ul><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT02594371?term=oraxol&amp;rank=4\" target=\"_blank\">Phase 3 clinical trial</a> assessing the safety and efficacy of Athenex's (<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color='green'>+1.3%</font>)&nbsp;Oraxol capsules compared to IV Taxol (paclitaxel) in patients with metastatic breast cancer will <a href=\"https://seekingalpha.com/pr/16960532-athenex-announces-positive-recommendations-drug-safety-monitoring-board-continue-oraxol-phase\" target=\"_blank\">continue as planned</a>. The decision followed a planned interim analysis by the independent Drug Safety Monitoring Board &#40;DSMB&#41; on 90 patients that completed treatment.</li><li>On the safety front, the incidence of painful neuropathy was \"uncommon\" in the Oraxol group, a prominent side-effect of Taxol that occurs in as many as 60% of patients (<a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf\" target=\"_blank\">p28 in package insert</a>).</li><li>A second interim analysis, based on 180 patients, will be done next year.</li><li>The co-primary endpoints are tumor response at weeks 19 - 22 and safety and tolerability up to 48 weeks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299578\" data-linked=\"Athenex&#39;s late-stage study comparing Oraxol to Taxol to continue as planned; shares up 1%\" data-tweet=\"$ATNX - Athenex&#39;s late-stage study comparing Oraxol to Taxol to continue as planned; shares up 1% https://seekingalpha.com/news/3299578-athenexs-late-stage-study-comparing-oraxol-to-taxol-to-continue-planned-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299578-athenexs-late-stage-study-comparing-oraxol-to-taxol-to-continue-planned-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299575\" data-ts=\"1507219080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVI\" target=\"_blank\">NAVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299575-navient-plunges-after-subprime-loan-lawsuit-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navient plunges after subprime loan lawsuit (update)</a></h4><ul><li>The Pennsylvania Attorney General&rsquo;s Office <a href=\"https://www.cnbc.com/2017/10/05/pennsylvania-attorney-general-files-suit-against-student-loan-provider-navient-for-deceptive-practices.html\" target=\"_blank\">files a lawsuit</a> against student loan company Navient (NASDAQ:<a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a>) alleging subprime loans.</li><li>The suit says Navient loaned to students attending schools with low graduation rates and &ldquo;an extremely high percentage&rdquo; of the students couldn&rsquo;t repay the loans.</li><li>\"Navient's deceptive practices and predatory conduct harmed student borrowers and put their own profits ahead of the interests of millions of families across our country who are struggling to repay student loans,\" says Attorney General Josh Shapiro.</li><li>Navient shares are&nbsp;<font color='red'>down 11.36%</font>.</li><li>Update: Navient <a href=\"http://www.reuters.com/article/brief-navient-issues-statement-on-claims/brief-navient-issues-statement-on-claims-made-by-pennsylvania-ag-idUSFWN1MG0IM?feedType=RSS&amp;feedName=companyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29\" target=\"_blank\">responds </a>by saying there \"are no allegations\" the company has broken the federal government's rules for student loan programs.</li><li>Navient shares are&nbsp;<font color='red'>down 12.69%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3299575\" data-linked=\"Navient plunges after subprime loan lawsuit (update)\" data-tweet=\"$NAVI - Navient plunges after subprime loan lawsuit (update) https://seekingalpha.com/news/3299575-navient-plunges-after-subprime-loan-lawsuit-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3299575-navient-plunges-after-subprime-loan-lawsuit-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299570\" data-ts=\"1507217846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299570-deutsche-bank-downgrades-western-digital-on-toshiba-nand-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank downgrades Western Digital on Toshiba, NAND concerns</a></h4><ul><li>        Deutsche Bank <a href=\"https://thefly.com/landingPageNews.php?id=2618705&amp;headline=WDC;TOSYY-Western-Digital-Toshiba-also-use-TOSBF-rating-change-\" target=\"_blank\">downgrades</a> Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) from Buy to Hold and lowers the price target from $105 to $80.</li><li>               Analyst Sherri Scribner tells investors to take a &ldquo;wait-and-see approach&rdquo; due to the uncertainty around Toshiba&rsquo;s chip unit sale and a NAND cycle that&rsquo;s nearing its peak heading into a 2018 easing.&nbsp;</li><li>               Western Digital wasn&rsquo;t part of Toshiba&rsquo;s winning consortium but has filed arbitration claiming contractual consent rights to the chip unit sale. Toshiba denies those rights exist and says the arbitration will, at worst, cause it to strip out the joint ventures with Western Digital and lower the chip unit selling price.&nbsp;</li><li>               Western Digital shares are&nbsp;<font color='red'>down 0.88%.</font>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299315-toshiba-says-western-digital-right-approve-chip-sale\" target=\"_blank\">Toshiba again says Western Digital has no right to approve chip sale</a> (Oct. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299454-bain-plans-sell-toshiba-chip-unit-time\" target=\"_blank\">Bain plans to sell Toshiba chip unit in time</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299570\" data-linked=\"Deutsche Bank downgrades Western Digital on Toshiba, NAND concerns\" data-tweet=\"$WDC - Deutsche Bank downgrades Western Digital on Toshiba, NAND concerns https://seekingalpha.com/news/3299570-deutsche-bank-downgrades-western-digital-on-toshiba-nand-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3299570-deutsche-bank-downgrades-western-digital-on-toshiba-nand-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299569\" data-ts=\"1507217443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299569-omeros-settles-omidria-patent-dispute-par-pharma-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros settles Omidria patent dispute with Par Pharma; shares up 6%</a></h4><ul><li>Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+6.4%</font>) <a href=\"https://seekingalpha.com/pr/16961030-omeros-announces-settlement-infringement-suit-anda-filer-par\" target=\"_blank\">settles </a>its <a href=\"http://www.omidria.com/\" target=\"_blank\">OMIDRIA </a>(phenylephrine and ketorolac injection) patent infringement litigation with generic challenger Par Pharmaceuticals.</li><li>Under the terms of the settlement, Par will be prohibited from launching a generic version of the eye drug until April 1, 2032. If and when Par does launch, Omeros will earn a 15% royalty on net sales until the last of its patents expires on October 23, 2033.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299569\" data-linked=\"Omeros settles Omidria patent dispute with Par Pharma; shares up 6%\" data-tweet=\"$OMER - Omeros settles Omidria patent dispute with Par Pharma; shares up 6% https://seekingalpha.com/news/3299569-omeros-settles-omidria-patent-dispute-par-pharma-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3299569-omeros-settles-omidria-patent-dispute-par-pharma-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299568\" data-ts=\"1507217083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299568-grubhubminus-4-citi-heads-to-sidelines-after-price-run\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub -4% as Citi heads to sidelines after price run</a></h4><ul>   <li>GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a>) is <font color='red'>off 4%</font> to its lowest point in a couple of weeks, as Citigroup downgrades shares to Neutral after a decent share-price run.</li>    <li>Investors may be <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10144671/investors-are-overestimating-the-near-term-benefit-to-g\" target=\"_blank\">overestimating the gain</a> GrubHub gets from its Eat24 acquisition, analyst Mark May says, noting that synergies may take longer to attain than expected.</li>    <li>GrubHub has moved <font color='green'>up 12%</font> since its Aug. 3 announcement of a $287.5M deal to buy Eat24 from Yelp, and shares are <font color='green'>up 38.4%</font> YTD.</li>    <li>Citi has a fair value of $56 on shares; the stock is down to $51.99 today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299568\" data-linked=\"GrubHub -4% as Citi heads to sidelines after price run\" data-tweet=\"$GRUB - GrubHub -4% as Citi heads to sidelines after price run https://seekingalpha.com/news/3299568-grubhubminus-4-citi-heads-to-sidelines-after-price-run?source=tweet\" data-url=\"https://seekingalpha.com/news/3299568-grubhubminus-4-citi-heads-to-sidelines-after-price-run\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299566\" data-ts=\"1507216650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299566-mannkind-rally-continues-shares-up-40\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind rally continues, shares up 40%</a></h4><ul><li>MannKind (<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+40.4%</font>) builds on its torrid pace on more than a 4x surge in volume. Shares have rallied over 164% in a week.</li><li>Several days ago the FDA approved updated labeling for inhaled fast-acting insulin AFREZZA.</li><li>The company's cash/cash equivalent balance was $43.4M at the end of June, which included $19.4M in borrowings from the Mann Group. Operations consumed $11.5M in H1.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298631-mannkind-ahead-9-percent-premarket-afrezza-label-update\" target=\"_blank\">MannKind ahead 9% premarket on Afrezza label update</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299566\" data-linked=\"MannKind rally continues, shares up 40%\" data-tweet=\"$MNKD - MannKind rally continues, shares up 40% https://seekingalpha.com/news/3299566-mannkind-rally-continues-shares-up-40?source=tweet\" data-url=\"https://seekingalpha.com/news/3299566-mannkind-rally-continues-shares-up-40\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299563\" data-ts=\"1507215992\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNOV\" target=\"_blank\">MNOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299563-profit-taking-sinks-medicinova-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Profit-taking sinks MediciNova, down 15%</a></h4><ul><li>Thinly traded micro cap MediciNova (<a href='https://seekingalpha.com/symbol/MNOV' title='MediciNova, Inc.'>MNOV</a> <font color='red'>-14.5%</font>) slips on more than double normal volume, albeit on turnover of only 160K shares, in apparent profit-taking after its<font color='green'> 60%</font>&nbsp;runup since mid-August.</li><li>On October 28, data from a mid-stage study of ibudilast (MN-166) in progressive multiple sclerosis will be <a href=\"https://seekingalpha.com/pr/16926872-medicinova-announces-abstract-mnminus-166-ibudilast-sprint-ms-phase-2b-study-progressive-ms\" target=\"_blank\">presented </a>at the Joint ECTRIMS-ACTRIMS Meeting in Paris, France.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3231434-medicinovas-mid-stage-study-mnminus-166-progressive-ms-continue-planned\" target=\"_blank\">MediciNova's mid-stage study of MN-166 in progressive MS to continue as planned</a> (Dec. 19, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299563\" data-linked=\"Profit-taking sinks MediciNova, down 15%\" data-tweet=\"$MNOV - Profit-taking sinks MediciNova, down 15% https://seekingalpha.com/news/3299563-profit-taking-sinks-medicinova-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3299563-profit-taking-sinks-medicinova-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299564\" data-ts=\"1507215869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSTI\" target=\"_blank\">SSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299564-shotspotter-up-26-since-vegas-shooting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ShotSpotter up 26% since Vegas shooting</a></h4><ul> <li>ShotSpotter (NASDAQ:<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a>) is <font color='green'>up 3.95%</font> on the day on strong volume.</li> <li>The gunfire-detecting stock is now up 27% since the mass shooting in Las Vegas.</li><li>investors appear to betting on potential upside for ShotSpotter with municipalities likely to assess the service.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299564\" data-linked=\"ShotSpotter up 26% since Vegas shooting\" data-tweet=\"$SSTI - ShotSpotter up 26% since Vegas shooting https://seekingalpha.com/news/3299564-shotspotter-up-26-since-vegas-shooting?source=tweet\" data-url=\"https://seekingalpha.com/news/3299564-shotspotter-up-26-since-vegas-shooting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299540\" data-ts=\"1507215635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299540-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='green'>+23%</font>. ITEK <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DRAD' title='Digirad Corporation'>DRAD</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/MNOV' title='MediciNova, Inc.'>MNOV</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-13%</font>. EBIO <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299540\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$APVO $MNKD $GNCA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3299540-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3299540-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299560\" data-ts=\"1507215206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRAD\" target=\"_blank\">DRAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299560-digirad-services-agreement-philips-over-year-end-shares-down-28\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digirad services agreement with Philips over at year-end; shares down 28%</a></h4><ul><li>Thinly traded nano cap Digirad (<a href='https://seekingalpha.com/symbol/DRAD' title='Digirad Corporation'>DRAD</a> <font color='red'>-27.9%</font>) slumps on a 9x surge in volume, albeit on turnover of only 367K shares, in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/707388/000070738817000027/a8-kphilips.htm\" target=\"_blank\">disclosure </a>that subsidiary DMS Health Technologies' services agreement with Philips will end on December 31.</li><li>DMS provided service contract sales and installation services for Philips' imaging systems, patient monitoring systems and other equipment in a relationship that started in April 2014. It will continue to provide warranty services for selected customers until such periods end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299560\" data-linked=\"Digirad services agreement with Philips over at year-end; shares down 28%\" data-tweet=\"$DRAD - Digirad services agreement with Philips over at year-end; shares down 28% https://seekingalpha.com/news/3299560-digirad-services-agreement-philips-over-year-end-shares-down-28?source=tweet\" data-url=\"https://seekingalpha.com/news/3299560-digirad-services-agreement-philips-over-year-end-shares-down-28\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299559\" data-ts=\"1507214816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299559-nuggets-on-potential-seaworld-buyout-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuggets on a potential SeaWorld buyout deal</a></h4><ul> <li>Axios reasons that Merlin Entertainment is likely to limits its pursuit to Busch Gardens instead of all of SeaWorld Entertainment (<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a> <font color='red'>-2.5%</font>).</li><li>Dan Primack reminds that Merlin has an internal policy against keeping marine mammals in captivity. A <a href=\"https://www.merlinentertainments.biz/sea-life\" target=\"_blank\">scan</a> of Merlin's website confirms his assertion.</li><li>\"Since we began back in 1979 we&rsquo;ve held firm to the belief that cetaceans &ndash; marine mammals like whales and dolphins &ndash; should not be kept in captivity,\" reads one of Merlin's pages.</li>  <li>Another nugget from Axios is on the deal price: \"Key number is 23. That's the per share price that China's Zhonghong Zhuoye Group paid earlier this year to buy a 21% stake in Sea World from The Blackstone Group.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298744-options-activity-seaworld-entertainment-picks\" target=\"_blank\">Options activity on SeaWorld Entertainment picks up</a> (Oct. 2)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299406-seaworld-jumps-7-percent-report-buyer-interest\" target=\"_blank\">Seaworld jumps 7% on report of buyer interest</a> (Oct. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299480-seaworld-entertainment-spotlight\" target=\"_blank\">SeaWorld Entertainment in the spotlight</a> (Oct. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299559\" data-linked=\"Nuggets on a potential SeaWorld buyout deal\" data-tweet=\"$SEAS - Nuggets on a potential SeaWorld buyout deal https://seekingalpha.com/news/3299559-nuggets-on-potential-seaworld-buyout-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3299559-nuggets-on-potential-seaworld-buyout-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299558\" data-ts=\"1507214178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTXS\" target=\"_blank\">CTXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299558-citrix-systems-announces-restructuring-program-employee-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citrix Systems announces restructuring program with employee cuts</a></h4><ul><li>        Citrix Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CTXS' title='Citrix Systems, Inc.'>CTXS</a>) <a href=\"https://seekingalpha.com/filing/3719868\" target=\"_blank\">announces</a> a restructuring program to support its previously announced transformation to a cloud-based subscription business.</li><li>                  The program includes cutting full-time positions and consolidating existing facilities.    </li><li>               Citrix expects to record $60M to $100M in pre-tax restructuring charges with $55M to $70M in pre-tax charges related to employee severance and $5M to $30M for facility consolidation.&nbsp;</li><li>               Citrix anticipates completing most of the restructuring activities during Q4 and during FY18. &nbsp;&nbsp;</li><li>Citrix shares are&nbsp;<font color='green'>up 1.16%.</font>&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3299558\" data-linked=\"Citrix Systems announces restructuring program with employee cuts\" data-tweet=\"$CTXS - Citrix Systems announces restructuring program with employee cuts https://seekingalpha.com/news/3299558-citrix-systems-announces-restructuring-program-employee-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3299558-citrix-systems-announces-restructuring-program-employee-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299556\" data-ts=\"1507213956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299556-sanofi-regeneron-win-appeal-of-pcsk9-patent-ruling-versus-amgen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi &amp; Regeneron win appeal of PCSK9 patent ruling versus Amgen</a></h4><ul><li>In a setback for Repatha (evolocumab) maker Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-1.4%</font>), a U.S. appeals court has <a href=\"http://www.kitco.com/news/2017-10-05/U-S-court-reverses-ban-on-sales-of-Sanofi-Regeneron-drug-Praluent.html\" target=\"_blank\">thrown out</a> the ban on sales of Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.2%</font>) and Regeneron's (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+1.8%</font>) Praluent (alirocumab) that a district court instituted in their patent infringement litigation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3241716-sanofi-regeneron-aint-dead-yet-praluent-court-allows-sales-continue-appeal-amgen-2-percent\" target=\"_blank\">Sanofi and Regeneron \"ain't dead yet\" with Praluent, court allows sales to continue during appeal; Amgen down 2% after hours</a> (Feb. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299556\" data-linked=\"Sanofi &amp; Regeneron win appeal of PCSK9 patent ruling versus Amgen\" data-tweet=\"$AMGN $AMGN $SNY - Sanofi &amp; Regeneron win appeal of PCSK9 patent ruling versus Amgen https://seekingalpha.com/news/3299556-sanofi-regeneron-win-appeal-of-pcsk9-patent-ruling-versus-amgen?source=tweet\" data-url=\"https://seekingalpha.com/news/3299556-sanofi-regeneron-win-appeal-of-pcsk9-patent-ruling-versus-amgen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299554\" data-ts=\"1507213818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299554-natural-gas-inventory-build-comes-in-lower-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory build comes in lower than expected</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>:  <strong>+42 Bcf </strong>vs. +51 Bcf consensus, +58 Bcf last week.</li><li>Futures&nbsp;<font color='green'>+1.16%</font>&nbsp;to $2.974.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299554\" data-linked=\"Natural gas inventory build comes in lower than expected\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory build comes in lower than expected https://seekingalpha.com/news/3299554-natural-gas-inventory-build-comes-in-lower-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3299554-natural-gas-inventory-build-comes-in-lower-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299548\" data-ts=\"1507212779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIA\" target=\"_blank\">ACIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299548-optical-equipment-stocks-fall-neophotonics-puts-china-demand-in-focus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Optical equipment stocks fall as NeoPhotonics puts China demand in focus</a></h4><ul>   <li>Optical equipment makers are lower in concert this morning after word of <a href=\"https://seekingalpha.com/news/3299534-neophotonics-minus-10_4-percent-amid-job-cuts-downbeat-early-q3-numbers\" target=\"_blank\">job cuts at NeoPhotonics</a> (<a href=\"http://seekingalpha.com/symbol/NPTN\" target=\"_blank\">NPTN</a> <font color='red'>-11.1%</font>) provides a hint that increased demand in China isn't materializing.</li>    <li>Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) is <font color='red'>down 3.1%</font>; Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>) <font color='red'>-0.9%</font>; Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) <font color='red'>-1.1%</font>; Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) <font color='red'>-1%</font>; and Lumentum Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) <font color='red'>-0.9%</font>.</li>    <li>NeoPhotonics draws 60% of its revenue from China, one of the biggest exposures to the Middle Kingdom, followed by Oclaro and Acacia.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299548\" data-linked=\"Optical equipment stocks fall as NeoPhotonics puts China demand in focus\" data-tweet=\"$ACIA $ACIA $OCLR - Optical equipment stocks fall as NeoPhotonics puts China demand in focus https://seekingalpha.com/news/3299548-optical-equipment-stocks-fall-neophotonics-puts-china-demand-in-focus?source=tweet\" data-url=\"https://seekingalpha.com/news/3299548-optical-equipment-stocks-fall-neophotonics-puts-china-demand-in-focus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299547\" data-ts=\"1507212105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299547-regeneron-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regeneron trading halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+2.3%</font>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299547\" data-linked=\"Regeneron trading halted pending news\" data-tweet=\"$REGN - Regeneron trading halted pending news https://seekingalpha.com/news/3299547-regeneron-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3299547-regeneron-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299543\" data-ts=\"1507211919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299543-investors-scramble-to-assess-amazon-fedex-ups-wildcards\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors scramble to assess Amazon/FedEx/UPS wildcards</a></h4><ul> <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) is now <font color='red'>down only 0.42%</font> and UPS (NYSE:<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a>) is <font color='red'>off 0.98%</font> as some of the early fears on news of an Amazon test of delivery peel back.</li> <li>Though the test is small in scale, analysts think the implications could be significant.</li> <li>\"Given the investments that Amazon is making in fulfillment infrastructure and transportation to support its own retail business, we view it simply a matter of time until they offer these services to third parties more broadly,\" notes Baird analyst Colin Sebastian.</li> <li>Morgan Stanley analyst Ravi Shanker says it's not a stretch that Amazon one day delivers goods for seller who don't even sell on Amazon. The firm says in a rough estimate that UPS has revenue exposure to Amazon of 5% to 10% and FedEx's exposure is at 3%.</li> <li>Sources: CNBC and Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299462-amazon-tests-delivery-service\" target=\"_blank\">Amazon tests delivery service</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299470-european-postal-names-tremble-amazon-news\" target=\"_blank\">European postal names tremble off Amazon news</a> (Oct. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299543\" data-linked=\"Investors scramble to assess Amazon/FedEx/UPS wildcards\" data-tweet=\"$FDX $FDX $UPS - Investors scramble to assess Amazon/FedEx/UPS wildcards https://seekingalpha.com/news/3299543-investors-scramble-to-assess-amazon-fedex-ups-wildcards?source=tweet\" data-url=\"https://seekingalpha.com/news/3299543-investors-scramble-to-assess-amazon-fedex-ups-wildcards\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299541\" data-ts=\"1507211849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RLMD\" target=\"_blank\">RLMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299541-relmada-secures-6_9m-private-capital-raise-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Relmada secures $6.9M private capital raise; shares up 6%</a></h4><ul><li>Relmada Therapeutics (<a href='https://seekingalpha.com/symbol/RLMD' title='Relmada Therapeutics, Inc.'>OTCQB:RLMD</a> <font color='green'>+5.6%</font>) inks an <a href=\"https://seekingalpha.com/pr/16960508-relmada-therapeutics-announces-6_9-million-private-placement\" target=\"_blank\">agreement </a>for the direct sale of convertible promissory notes and warrants that will yield gross proceeds of ~$6.9M.</li><li>The company will issue $6.89M in two-year 7% convertible promissory notes that will automatically convert into common stock in a future equity financing. It will also issue seven-year warrants to purchase up to 4,593,333 common shares at $1.50.</li><li>Net proceeds will fund the advancement of dextromethadone for the treatment of major depressive disorder.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299541\" data-linked=\"Relmada secures $6.9M private capital raise; shares up 6%\" data-tweet=\"$RLMD - Relmada secures $6.9M private capital raise; shares up 6% https://seekingalpha.com/news/3299541-relmada-secures-6_9m-private-capital-raise-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3299541-relmada-secures-6_9m-private-capital-raise-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299534\" data-ts=\"1507209900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NPTN\" target=\"_blank\">NPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299534-neophotonicsminus-10_4-amid-job-cuts-downbeat-early-q3-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoPhotonics -10.4% amid job cuts, downbeat early Q3 numbers</a></h4><ul>   <li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) is <font color='red'>down 10.4%</font> in premarket action after it <a href=\"https://seekingalpha.com/pr/16960362-neophotonics-announces-restructuring-actions-preliminary-financial-results-third-quarter\" target=\"_blank\">announced restructuring actions</a> that will lead to job cuts, along with preliminary Q3 financials.</li>    <li>Restructuring actions include a force reduction along with real estate consolidation, a writedown of some inventory, and a writedown of idle assets.</li>    <li>&ldquo;Lacking a clear indication of increased demand in China in the third quarter, we initiated several operational changes with the goal of expediting our return to profitability,\" says CEO/Chairman Tim Jenks.</li>    <li>The company's expecting costs of the actions of $4.8M ($4.2M in asset writeoffs and $0.6M in severance), incurring about $4.6M of that in Q3. But it's looking to immediately cut quarterly expenses, and expects a $2M reduction when fully realized in Q1 2018.</li>    <li>Meanwhile for Q3, preliminary revenues are seen at $69M-$71M (below consensus for $73.5M) and GAAP EPS is -$0.50 to -$0.40 (well below an expected -$0.16). Non-GAAP EPS is seen at -$0.35 to -$0.27 (vs. consensus for -$0.12).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299534\" data-linked=\"NeoPhotonics -10.4% amid job cuts, downbeat early Q3 numbers\" data-tweet=\"$NPTN - NeoPhotonics -10.4% amid job cuts, downbeat early Q3 numbers https://seekingalpha.com/news/3299534-neophotonicsminus-10_4-amid-job-cuts-downbeat-early-q3-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299534-neophotonicsminus-10_4-amid-job-cuts-downbeat-early-q3-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299533\" data-ts=\"1507209807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299533-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+25%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299417-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li><li><a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+22%</font>&nbsp;on stock <a href=\"https://seekingalpha.com/news/3299479-caredx-prices-stock-offering-4-shares-3-percent-premarket\" target=\"_blank\">offering</a>.</li><li><a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a> <font color='green'>+16%</font>&nbsp;as&nbsp;Rhode Island Blood Center received <a href=\"https://seekingalpha.com/pr/16960583-cerus-announces-first-biologics-license-application-approval-u-s-blood-center-customer\" target=\"_blank\">FDA</a><a href=\"https://seekingalpha.com/pr/16960583-cerus-announces-first-biologics-license-application-approval-u-s-blood-center-customer\" target=\"_blank\">&nbsp;</a><a href=\"https://seekingalpha.com/pr/16960583-cerus-announces-first-biologics-license-application-approval-u-s-blood-center-customer\" target=\"_blank\">&nbsp;approval</a>.</li><li><a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='green'>+9%</font>&nbsp;on positive safety and immune response <a href=\"https://seekingalpha.com/pr/16960400-inovio-s-positive-zika-vaccine-clinical-study-data-published-new-england-journal-medicine\" target=\"_blank\">results</a> from a first-in-man, multi-center phase 1 trial of a vaccine against the Zika virus.</li><li><a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='green'>+8%</font>&nbsp;on strategic <a href=\"https://seekingalpha.com/news/3299503-destination-maternity-offensive\" target=\"_blank\">initiatives</a>.</li><li><a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299378-collegium-inks-deal-cigna-oxycodone-equivalent-share-rise-1-percent\" target=\"_blank\">deal</a> with Cigna for Oxycodone equivalent.</li><li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299359-celsion-raises-15_6m-exercise-warrants\" target=\"_blank\">raising</a> $15.6M capital from exercise of warrants.</li><li><a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a> <font color='green'>+6%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3299489-constellation-brands-beats-0_30-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299413-acadia-launches-late-stage-study-nuplazid-dementia-related-psychosis-shares-ahead-4-percent\" target=\"_blank\">launching</a> late-stage study of Nuplazid in dementia-related psychosis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299533\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$APVO $CDNA $CERS - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3299533-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3299533-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299532\" data-ts=\"1507209706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INO\" target=\"_blank\">INO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299532-inovios-zika-vaccine-shows-positive-effect-in-early-stage-study-shares-ahead-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio&#39;s Zika vaccine shows positive effect in early-stage study; shares ahead 10% premarket</a></h4><ul><li>Inovio Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a>) is up&nbsp;<font color='green'>10%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16960400-inovio-s-positive-zika-vaccine-clinical-study-data-published-new-england-journal-medicine\" target=\"_blank\">announcement </a>of positive data from a Phase 1 clinical trial, ZIKA-001, assessing DNA-based Zika vaccine GLS-5700. The results were just <a href=\"http://www.nejm.org/doi/full/10.1056/NEJMoa1708120?query=featured_home\" target=\"_blank\">published</a> in the <em>New England Journal of Medicine</em>.</li><li>A three-dose vaccination regimen induced binding antibodies in 100% (n=40/40) of subjects and in 95% (n=38/40) after two doses. Neutralizing antibodies were observed on more than 95% of serum samples that were assayed on neuronal-cell targets.</li><li>A second Phase 1 being conducted in Puerto Rico is fully enrolled with 160 participants who are dengue virus-positive.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294672-inovios-inominus-5150-shows-treatment-effect-early-stage-prostate-cancer-study\" target=\"_blank\">Inovio's INO-5150 shows treatment effect in early-stage prostate cancer study</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299532\" data-linked=\"Inovio&#39;s Zika vaccine shows positive effect in early-stage study; shares ahead 10% premarket\" data-tweet=\"$INO - Inovio&#39;s Zika vaccine shows positive effect in early-stage study; shares ahead 10% premarket https://seekingalpha.com/news/3299532-inovios-zika-vaccine-shows-positive-effect-in-early-stage-study-shares-ahead-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299532-inovios-zika-vaccine-shows-positive-effect-in-early-stage-study-shares-ahead-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299530\" data-ts=\"1507209552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299530-piper-jaffray-cautious-on-coach-kate-spade-integration-plays-out\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray cautious on Coach as Kate Spade integration plays out</a></h4><ul> <li>Coach (COH)&nbsp;trades lower after taking on a <a href=\"https://www.cnbc.com/2017/10/05/early-movers-msft-amzn-ups-fdx-kmx-seas-sonc-vz-more.html\" target=\"_blank\">downgrade</a> from Piper Jaffray.</li> <li>Analyst Erinn Murphy lowers the apparel stock to Neutral from Overweight on the expectation that Coach may underperform.</li> <li>Murphy also wants to wait out the Kate Spade integration period to get a clearer picture of the long-term potential from the \"tranformational\" acquisition.</li> <li>COH <font color='red'>-1.01%</font> premarket to $39.32.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299530\" data-linked=\"Piper Jaffray cautious on Coach as Kate Spade integration plays out\" data-tweet=\"$TPR - Piper Jaffray cautious on Coach as Kate Spade integration plays out https://seekingalpha.com/news/3299530-piper-jaffray-cautious-on-coach-kate-spade-integration-plays-out?source=tweet\" data-url=\"https://seekingalpha.com/news/3299530-piper-jaffray-cautious-on-coach-kate-spade-integration-plays-out\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299529\" data-ts=\"1507209444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299529-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299387-streamline-health-sells-pre-bill-code-auditing-technology-west-coast-customer-shares-50\" target=\"_blank\">selling</a> pre-bill code auditing technology to Wast Cast customer.</li><li><a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16960362-neophotonics-announces-restructuring-actions-preliminary-financial-results-third-quarter\" target=\"_blank\">announcing</a> restructuring actions and preliminary Q3 results.</li><li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-12%</font>.</li><li>EBIO <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16960398-vericel-provides-business-updates-2017-cell-and-gene-meeting-mesa\" target=\"_blank\">providing</a> business update.</li><li><a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299396-immunogen-readies-13m-share-stock-offering-shares-3-percent-hours\" target=\"_blank\">announcing</a> proposed public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299432-globalstar-minus-3_7-percent-plans-125m-equity-offering\" target=\"_blank\">plans</a> for $125M equity offering.</li><li><a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a>&nbsp;<font color='red'>-7%</font>&nbsp;after an <a href=\"https://seekingalpha.com/news/3299495-stats-feuerstein-rains-endocytes-parade-says-prostate-drug-likely-work-shares-8-percent\" target=\"_blank\">article</a> by STAT''s Adam Feuerstein.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299529\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$STRM $NPTN $TEUM - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3299529-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3299529-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299519\" data-ts=\"1507208111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299519-new-data-show-earlier-start-of-treatment-spinraza-may-improve-motor-function-in-sma-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New data show earlier start of treatment with Spinraza may improve motor function in SMA patients; Biogen up 2% premarket</a></h4><ul><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) is up&nbsp;<font color='green'>2%&nbsp;</font>premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16960421-biogen-s-spinraza-nusinersen-data-show-earlier-treatment-initiation-may-lead-improved-motor\" target=\"_blank\">announcement </a>of encouraging new data on spinal muscular atrophy &#40;SMA&#41; med SPINRAZA (nusinersen). The results were presented at the World Muscle Society Conference in France.</li><li>Data from the Phase 3 ENDEAR study showed infants with SMA who initiated treatment earlier in the disease experienced greater improvements in motor function. Specifically, infants with disease duration of no more than 12 weeks treated with SPINRAZA showed a superior rate of response compared to untreated infants (75% vs. 0%; p&lt;0001). In infants with disease duration greater than 12 weeks, the response rate still greatly favored SPINRAZA (32% vs. 0%; p=0.0026). SPINRAZA also showed a treatment benefit in event-free survival in the short-disease-duration group (p=0.0004).</li><li>Nusinersen licensor Ionis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) is also up&nbsp;<font color='green'>2%</font>&nbsp;premarket, albeit on only 600 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299519\" data-linked=\"New data show earlier start of treatment with Spinraza may improve motor function in SMA patients; Biogen up 2% premarket\" data-tweet=\"$BIIB $BIIB $IONS - New data show earlier start of treatment with Spinraza may improve motor function in SMA patients; Biogen up 2% premarket https://seekingalpha.com/news/3299519-new-data-show-earlier-start-of-treatment-spinraza-may-improve-motor-function-in-sma-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3299519-new-data-show-earlier-start-of-treatment-spinraza-may-improve-motor-function-in-sma-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299523\" data-ts=\"1507207802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299523-canaccord-genuity-upgrades-microsoft-on-growth-drivers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord Genuity upgrades Microsoft on growth drivers</a></h4><ul><li>        Canaccord Genuity <a href=\"https://timesofindia.indiatimes.com/business/international-business/microsoft-canaccord-sees-long-term-growth-potential-raises-to-buy/articleshow/60951458.cms\" target=\"_blank\">upgrades</a> Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) from Hold to Buy.</li><li>                  The firm says investors underestimate growth drivers including Office, gaming, and Azure&rsquo;s PaaS that can lead to sustainable growth acceleration.    </li><li>               Canaccord expects total revenue growth to accelerate from a 6% growth in FY17 to between 11% and 15% growth in FY22.&nbsp;</li><li>               Firm sees share prices reaching $115 to $120 by CY20.&nbsp;</li><li>Microsoft shares are&nbsp;<font color='green'>up 1.06%&nbsp;</font>premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3299523\" data-linked=\"Canaccord Genuity upgrades Microsoft on growth drivers\" data-tweet=\"$MSFT - Canaccord Genuity upgrades Microsoft on growth drivers https://seekingalpha.com/news/3299523-canaccord-genuity-upgrades-microsoft-on-growth-drivers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299523-canaccord-genuity-upgrades-microsoft-on-growth-drivers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299514\" data-ts=\"1507206866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMCF\" target=\"_blank\">RMCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299514-on-rocky-mountain-chocolate-factorys-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Rocky Mountain Chocolate Factory&#39;s Q2</a></h4><ul><li>Rocky Mountain Chocolate Factory (NASDAQ:<a href='https://seekingalpha.com/symbol/RMCF' title='Rocky Mountain Chocolate Factory, Inc.'>RMCF</a>) reports retail same-store sales declined 4.1% in <a href=\"https://seekingalpha.com/pr/16960515-rocky-mountain-chocolate-factory-inc-reports-first-six-months-fiscal-year-2018-operating\" target=\"_blank\">Q2</a>.</li><li>Total Factory sales fell 1.9% to $4.88M.</li><li>Retail sales declined 11.9% to $1.18M primarily due to sale and closure of certain company-owned stores and caf&eacute;s.</li><li>Royalties and marketing fees down 8.8% to $2.04M.</li><li>Franchise fees increased 229.3% to $0.16M primarily due to increase in international license fees.</li><li>Adjusted EBITDA decreased 0.2% to $2.01M.</li><li>Operating margin rate +10 bps to 18.2%.</li><li>Store count -13 Q/Q to 498.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299514\" data-linked=\"More on Rocky Mountain Chocolate Factory&#39;s Q2\" data-tweet=\"$RMCF - More on Rocky Mountain Chocolate Factory&#39;s Q2 https://seekingalpha.com/news/3299514-on-rocky-mountain-chocolate-factorys-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3299514-on-rocky-mountain-chocolate-factorys-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299507\" data-ts=\"1507206220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299507-medicines-cos-vabomere-beats-best-available-therapy-in-late-stage-study-in-carbapenem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Medicines Co&#39;s Vabomere beats best available therapy in late-stage study in carbapenem-resistant infections; shares ahead 6% premarket</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16960359-medicines-company-present-new-data-tango-ii-study-vabomere-meropenem-vaborbactam-idweek-2017\" target=\"_blank\">New data</a> from a Phase 3 clinical trial, TANGO II, assessing The Medicines Company's (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) VABOMERE (meropenem and vaborbactam) in patients with carbapenem-resistant Enterobacteriaceae infections showed a significant treatment benefit over \"best available therapy\" &#40;BAT&#41;. The results will be presented at IDWeek in San Diego.</li><li><a href=\"http://www.vabomere.com/?gclid=Cj0KCQjwsNfOBRCWARIsAGITapYviM6RPphP9iCGYi1YcJtV_AYsZJphKLxLyblgzVtCveamCmHR-fMaAhHEEALw_wcB\" target=\"_blank\">VABOMERE </a>showed a higher cure rate compared to BAT at the end of therapy (64.3% vs. 33.3%; p=0.04) and test-of-cure (57.1% vs. 26.7%; p=0.04). In immunocompromised patients, its superiority in clinical cure was more pronounced (60.0% vs. 12.5%; p&lt;0.01).</li><li>VABOMERE showed less nephrotoxicity and fewer treatment-related adverse events than BAT.</li><li>In July, the study was stopped early due to VABOMERE's significant treatment benefit. The FDA approved it in August under Priority Review status.</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292604-fda-oks-medicines-companys-vabomere-antibiotic-shares-ahead-6-percent-premarket\" target=\"_blank\">FDA OKs The Medicines Company's Vabomere antibiotic; shares ahead 6% premarket</a> (Aug. 30)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280892-late-stage-study-medicines-cos-antibiotic-combo-vabomere-stopped-early-u-s-approval-likely\" target=\"_blank\">Late-stage study of The Medicines Co's antibiotic combo Vabomere stopped early; U.S. approval likely this quarter; shares ahead 5% premarket</a> (July 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299507\" data-linked=\"The Medicines Co&#39;s Vabomere beats best available therapy in late-stage study in carbapenem-resistant infections; shares ahead 6% premarket\" data-tweet=\"$MDCO - The Medicines Co&#39;s Vabomere beats best available therapy in late-stage study in carbapenem-resistant infections; shares ahead 6% premarket https://seekingalpha.com/news/3299507-medicines-cos-vabomere-beats-best-available-therapy-in-late-stage-study-in-carbapenem?source=tweet\" data-url=\"https://seekingalpha.com/news/3299507-medicines-cos-vabomere-beats-best-available-therapy-in-late-stage-study-in-carbapenem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299505\" data-ts=\"1507205637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299505-tg-therapeutics-advances-anti-pd-l1-monoclonal-antibody-clinical-development-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics advances its anti-PD-L1 monoclonal antibody into clinical development; shares ahead 3% premarket</a></h4><ul> <li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <a href=\"https://seekingalpha.com/pr/16960430-tg-therapeutics-inc-announces-advancement-anti-pd-l1-monoclonal-antibody-clinical-development\" target=\"_blank\">announces</a> that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of its fully-human anti-PD-L1 monoclonal antibody in checkpoint therapy-na&iuml;ve patients with selected recurrent or metastatic cancers.</li><li>Secondary endpoints include the evaluation or characterization of the pharmacokinetics, immunogenicity and preliminary efficacy.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3299505\" data-linked=\"TG Therapeutics advances its anti-PD-L1 monoclonal antibody into clinical development; shares ahead 3% premarket\" data-tweet=\"$TGTX - TG Therapeutics advances its anti-PD-L1 monoclonal antibody into clinical development; shares ahead 3% premarket https://seekingalpha.com/news/3299505-tg-therapeutics-advances-anti-pd-l1-monoclonal-antibody-clinical-development-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3299505-tg-therapeutics-advances-anti-pd-l1-monoclonal-antibody-clinical-development-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>177&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299504\" data-ts=\"1507205419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STZ\" target=\"_blank\">STZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299504-constellation-brands-positive-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Constellation Brands positive on earnings beat</a></h4><ul>     <li>Constellation Brands (NYSE:<a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a>) reports organic net sales rose 8% to $2.07B in <a href=\"https://seekingalpha.com/pr/16960441-constellation-brands-reports-second-quarter-fiscal-2018-results\" target=\"_blank\">Q2</a>.</li>     <li>Beer segment sales increased 12.8% to $1.38B.</li>     <li>Wine and spirits sales fell 11.7% to $705.6M.</li>     <li>Adjusted gross margin rate expanded 290 bps to 50.9%.</li>     <li>Adjusted operating margin rate advanced 340 bps to 34.1%.</li>     <li>Shipment volume: Beer: 80.3M (+11.7%);&nbsp;Wine and spirits: 14.7M (-19.2%).</li>     <li><b>FY2018 Guidance</b>: Beer segment sales: +9% to +11%; Wine &amp; Spirits segment sales:&nbsp;-4% to -6%; Beer operating income: +17% to +19%; Wine &amp; Spirits operating income:&nbsp;flat; Interest expense: $330M to $340M; Tax rate: ~21%;&nbsp;Weighted average diluted shares outstanding: ~201M; Diluted EPS: $7.90 to $8.05; Adjusted diluted EPS: $8.25 to $8.40; Free cash flow: $725M to $825M; Operating cash flow: $1.9B to $2.1B; Capex: ~$1.175B to $1.275B.</li>     <li>STZ&nbsp;<font color='green'>+4.44%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299504\" data-linked=\"Constellation Brands positive on earnings beat\" data-tweet=\"$STZ - Constellation Brands positive on earnings beat https://seekingalpha.com/news/3299504-constellation-brands-positive-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3299504-constellation-brands-positive-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299498\" data-ts=\"1507205085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXTR\" target=\"_blank\">DXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299498-dextera-surgical-provides-corporate-update-shares-off-33-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dextera Surgical provides corporate update; shares off 33% premarket</a></h4><ul> <li>Dextera Surgical (<a href='https://seekingalpha.com/symbol/DXTR' title='Dextera Surgical Inc.'>OTC:DXTR</a>) <a href=\"https://seekingalpha.com/pr/16960351-dextera-surgical-provides-corporate-update\" target=\"_blank\">announces</a> that Q1 revenue for FY 2018 will be ~$568,000.</li><li>Julian Nikolchev, President and CEO says,&nbsp;&ldquo;As we have scaled up production of the MicroCutter 5/80, we have had difficulty qualifying some of the raw material for our reloads and as a result we experienced limited ability to ship product to our customers.\"</li>     <li>The Company will hold conference call today at 8:30 a.m. Eastern Time to discuss the issue.</li><li>Shares are down&nbsp;<font color='red'>33%</font>&nbsp;premarket on modest volume.</li>               </ul><div class=\"tiny-share-widget\" data-id=\"3299498\" data-linked=\"Dextera Surgical provides corporate update; shares off 33% premarket\" data-tweet=\"$DXTR - Dextera Surgical provides corporate update; shares off 33% premarket https://seekingalpha.com/news/3299498-dextera-surgical-provides-corporate-update-shares-off-33-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299498-dextera-surgical-provides-corporate-update-shares-off-33-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299417\" data-ts=\"1507204658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299417-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) initiated with Market Perform rating by Oppenheimer. Shares up a fraction premarket.</li><li>FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>) initiated with Neutral rating and $61 (2% upside) price target by Mizuho Securities.</li><li>Akebia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a>) initiated with Buy rating and $24 (25% upside) price target by Mizuho.</li><li>Aptevo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>) resumed with Overweight rating and $6 (159% upside) price target by Piper Jaffray. Shares up&nbsp;<font color='green'>24%</font>&nbsp;premarket.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) upgraded to Overweight by Morgan Stanley. Shares up&nbsp;<font color='green'>2%&nbsp;</font>premarket.</li><li>AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) upgraded to Outperform with a $96 (16% upside) price target by Robert W. Baird. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) downgraded to Underweight by Morgan Stanley citing looming generic threat to Revlimid. Shares down&nbsp;<font color='red'>3%&nbsp;</font>premarket.</li><li>Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a>) downgraded to Hold by Canaccord Genuity. Shares down&nbsp;<font color='red'>4%</font>&nbsp;premarket.</li><li>Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy'>DPLO</a>) price target raised to $23.75 (12% upside) following its acquisition of 8th Day Software.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3299417\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$GILD $GILD $FGEN - Premarket analyst action - healthcare https://seekingalpha.com/news/3299417-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3299417-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299496\" data-ts=\"1507204532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LC\" target=\"_blank\">LC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299496-lendingclub-up-1_4-after-sohn-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingClub up 1.4% after Sohn boost</a></h4><ul><li>Black-and-White Capital's Seth Wunder pitches LendingClub (NYSE:<a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>) at his Sohn San Francisco appearance.</li><li>The potential for high growth remains as the company's ability to originate loans isn't bound by its balance sheet. He sees the potential for $17 per share - a near triple - over the next couple of years.</li><li>Shares&nbsp;<font color='green'>+1.4%</font>&nbsp;premarket to $6.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299496\" data-linked=\"LendingClub up 1.4% after Sohn boost\" data-tweet=\"$LC - LendingClub up 1.4% after Sohn boost https://seekingalpha.com/news/3299496-lendingclub-up-1_4-after-sohn-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3299496-lendingclub-up-1_4-after-sohn-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299495\" data-ts=\"1507204463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECYT\" target=\"_blank\">ECYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299495-stats-feuerstein-rains-on-endocytes-parade-says-prostate-drug-not-likely-to-work-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STAT&#39;s Feuerstein rains on Endocyte&#39;s parade, says prostate drug not likely to work; shares down 8% premarket</a></h4><ul><li>Long investors in Endocyte (NASDAQ:<a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a>) are facing a down day on the heels of an <a href=\"https://www.statnews.com/2017/10/05/endoycte-hype-prostate-cancer/\" target=\"_blank\">article </a>by STAT's Adam Feuerstein who says its just-licensed prostate drug, PSMA-617, won't be a winner due to significant off-target toxicity associated with the PSMA target.</li><li>Shares rallied four-fold on the news, but they are down&nbsp;<font color='red'>8%</font>&nbsp;premarket on increased volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298652-endocyte-licenses-late-stage-prostate-cancer-candidate-abx-gmbh-shares-ahead-11-percent\" target=\"_blank\">Endocyte in-licenses late-stage prostate cancer candidate from ABX GmbH; shares ahead 11% premarket</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299495\" data-linked=\"STAT&#39;s Feuerstein rains on Endocyte&#39;s parade, says prostate drug not likely to work; shares down 8% premarket\" data-tweet=\"$ECYT - STAT&#39;s Feuerstein rains on Endocyte&#39;s parade, says prostate drug not likely to work; shares down 8% premarket https://seekingalpha.com/news/3299495-stats-feuerstein-rains-on-endocytes-parade-says-prostate-drug-not-likely-to-work-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3299495-stats-feuerstein-rains-on-endocytes-parade-says-prostate-drug-not-likely-to-work-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>74&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299492\" data-ts=\"1507204054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISCA\" target=\"_blank\">ISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299492-international-speedway-higher-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Speedway higher on earnings beat</a></h4><ul>     <li>International Speedway (NASDAQ:<a href='https://seekingalpha.com/symbol/ISCA' title='International Speedway Corporation'>ISCA</a>)&nbsp;reports admission revenue fell 0.3% to $22.77M in <a href=\"https://seekingalpha.com/pr/16960426-international-speedway-corporation-reports-financial-results-third-quarter-fiscal-2017\" target=\"_blank\">Q3</a>.</li>     <li>Motorsports&nbsp;and other event related&nbsp;revenue rose 4.2% to $94.03M.</li>     <li>Food, beverage, and merchandise revenue grew 2.5% to $11.12M.</li>     <li>Operating margin rate squeezed 130 bps to 1.6%.</li>     <li><b>FY2017 Guidance</b>: Revenue: $660M to $670M; Non-GAAP EBITDA: $208M to $218M; EBITDA margin: 31.5% to 32.5%; Operating margin: 15.5% to 17%; Tax rate: 38% to 38.5%; Diluted EPS: $1.50 to $1.65; Capex: ~$150M to $175M.</li>     <li>ISCA&nbsp;<font color='green'>+9.28%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299492\" data-linked=\"International Speedway higher on earnings beat\" data-tweet=\"$ISCA - International Speedway higher on earnings beat https://seekingalpha.com/news/3299492-international-speedway-higher-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3299492-international-speedway-higher-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299489\" data-ts=\"1507203655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STZ\" target=\"_blank\">STZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299489-constellation-brands-beats-0_30-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Constellation Brands beats by $0.30, beats on revenue</a></h4><ul><li>Constellation Brands (NYSE:<a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a>): Q2 EPS of $2.47 <font color='green'>beats by $0.30</font>.</li><li>Revenue of $2.08B (+3.0% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+1.4%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16960441-constellation-brands-reports-second-quarter-fiscal-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299489\" data-linked=\"Constellation Brands beats by $0.30, beats on revenue\" data-tweet=\"$STZ - Constellation Brands beats by $0.30, beats on revenue https://seekingalpha.com/news/3299489-constellation-brands-beats-0_30-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3299489-constellation-brands-beats-0_30-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299486\" data-ts=\"1507203164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISCA\" target=\"_blank\">ISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299486-international-speedway-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Speedway beats by $0.03, beats on revenue</a></h4><ul><li>International Speedway (NASDAQ:<a href='https://seekingalpha.com/symbol/ISCA' title='International Speedway Corporation'>ISCA</a>): Q3 EPS of $0.06 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $131.94M (+2.3% Y/Y) <font color='green'>beats by $3.12M</font>.</li><li>Shares <font color='green'>+9.28%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16960426-international-speedway-corporation-reports-financial-results-third-quarter-fiscal-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299486\" data-linked=\"International Speedway beats by $0.03, beats on revenue\" data-tweet=\"$ISCA - International Speedway beats by $0.03, beats on revenue https://seekingalpha.com/news/3299486-international-speedway-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3299486-international-speedway-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299484\" data-ts=\"1507203062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBIX\" target=\"_blank\">NBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299484-fda-oks-80-mg-capsule-for-neurocrines-ingrezza-wholesale-cost-will-be-207_50-shares-ahead-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs 80 mg capsule for Neurocrine&#39;s Ingrezza, wholesale cost will be $207.50; shares ahead 7% premarket</a></h4><ul><li>Neurocrine Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket, albeit on only 315 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16960360-neurocrine-announces-fda-approval-80-mg-ingrezza-valbenazine-capsules-treatment-adults\" target=\"_blank\">announcement</a> that the FDA has approved an 80 mg capsule strength for tardive dyskinesia med <a href=\"https://ingrezza.com/HCP/\" target=\"_blank\">INGREZZA </a>(valbenazine). The product was first approved in April in a 40 mg strength.</li><li>The recommended dosing regimen is 40 mg once daily for one week, then increase to 80 mg once daily.</li><li>The new 80 mg capsule will be available to patients within two weeks through a select pharmacy network. The <a href=\"https://www.sec.gov/Archives/edgar/data/914475/000119312517303863/d467268d8k.htm\" target=\"_blank\">wholesale acquisition cost </a>for a 30-count bottle will be $6,225.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299484\" data-linked=\"FDA OKs 80 mg capsule for Neurocrine&#39;s Ingrezza, wholesale cost will be $207.50; shares ahead 7% premarket\" data-tweet=\"$NBIX - FDA OKs 80 mg capsule for Neurocrine&#39;s Ingrezza, wholesale cost will be $207.50; shares ahead 7% premarket https://seekingalpha.com/news/3299484-fda-oks-80-mg-capsule-for-neurocrines-ingrezza-wholesale-cost-will-be-207_50-shares-ahead-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3299484-fda-oks-80-mg-capsule-for-neurocrines-ingrezza-wholesale-cost-will-be-207_50-shares-ahead-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299479\" data-ts=\"1507202465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNA\" target=\"_blank\">CDNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299479-caredx-prices-stock-offering-4-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CareDx prices stock offering at $4; shares up 3% premarket</a></h4><ul><li>CareDx (NASDAQ:<a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a>) <a href=\"https://www.streetinsider.com/Corporate+News/CareDx+%28CDNA%29+Prices+4.3M+Common+Stock+Offering+at+%244Share/13363905.html\" target=\"_blank\">prices </a>its public offering of 4,341,600 shares of common stock at $4 per share. Underwriters over-allotment is an additional 651,240 shares. Closing date is October 9.</li><li>Yesterday's close was $4.41. Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299479\" data-linked=\"CareDx prices stock offering at $4; shares up 3% premarket\" data-tweet=\"$CDNA - CareDx prices stock offering at $4; shares up 3% premarket https://seekingalpha.com/news/3299479-caredx-prices-stock-offering-4-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299479-caredx-prices-stock-offering-4-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299471\" data-ts=\"1507201072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIGL\" target=\"_blank\">RIGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299471-rigel-prices-stock-offering-3_35-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rigel prices stock offering at $3.35; shares down 5% premarket</a></h4><ul><li>Rigel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>) is off&nbsp;<font color='red'>5%&nbsp;</font>premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/16960235-rigel-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 18.1M shares of common stock at $3.35 per share. Underwriters over-allotment is an additional 2.715M shares. Closing date is October 10.</li><li>Yesterday's close was $3.62.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299471\" data-linked=\"Rigel prices stock offering at $3.35; shares down 5% premarket\" data-tweet=\"$RIGL - Rigel prices stock offering at $3.35; shares down 5% premarket https://seekingalpha.com/news/3299471-rigel-prices-stock-offering-3_35-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299471-rigel-prices-stock-offering-3_35-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299462\" data-ts=\"1507198754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299462-amazon-tests-delivery-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon tests delivery service</a></h4><ul> <li>Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) is <a href=\"https://www.bloomberg.com/news/articles/2017-10-05/amazon-is-said-to-test-own-delivery-service-to-rival-fedex-ups\" target=\"_blank\">testing out</a> a new delivery service that will make more products available for free two-day delivery.</li> <li>The program sees more deliveries made straight from the warehouses of its third-party merchants to the homes of customers. The method cuts down on warehouse overcrowding and could potentially reduce Amazon's reliance on FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) and UPS (NYSE:<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a>).</li><li>A broader roll-out is expected in 2018.</li> <li>In premarket trading, FedEx is <font color='red'>down 2%</font> and UPS is <font color='red'>off 3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299462\" data-linked=\"Amazon tests delivery service\" data-tweet=\"$AMZN $AMZN $FDX - Amazon tests delivery service https://seekingalpha.com/news/3299462-amazon-tests-delivery-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3299462-amazon-tests-delivery-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}